$CGON News

Did CG Oncology’s Leadership Consolidation Around CEO Kuan Just Shift CGON’s Commercialization Narrative?

CG Oncology to Present at Upcoming Investor Conferences in June

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Wolfe Research Initiates Coverage On CG Oncology with Peer Perform Rating

HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $100 Price Target

Assessing CG Oncology (CGON) Valuation After Positive Phase 2 CORE-008 Bladder Cancer Data

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

CG Oncology Reports First Results From CORE‑008 Cohort CX Phase 2 Trial

CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears

Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $82

CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript

CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

JP Morgan Maintains Overweight on CG Oncology, Raises Price Target to $96

CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings

RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $81

Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $77

CG Oncology Inc (NASDAQ:CGON) Shows Perfect Technical Rating and Strong Setup Quality for Potential Breakout

Wedbush Maintains Outperform on CG Oncology, Raises Price Target to $80

RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst